---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-056708"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:29:18.404528+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience relaunches as Whitehawk Therapeutics; reports FY2024 net loss $63.7M, $100M PIPE closed

## Summary
- Name changed to Whitehawk Therapeutics; stock begins trading under 'WHWK' on Nasdaq effective March 19, 2025.
- Closed $100M PIPE financing; pending divestiture of FYARRO business to Kaken Pharmaceuticals.
- Cash position $47.2M at Dec 31, 2024; expected $170-180M after transactions, funding operations into 2028.
- FY2024 total revenue $26.0M from FYARRO; net loss $63.7M vs $65.8M in 2023.
- ADC portfolio: three assets targeting PTK7, MUC16, SEZ6; goal to bring all to IND within 15 months.

## SEC filing metadata
- accession: 0001193125-25-056708
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01, 5.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/d839636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-056708
- JSON: https://secwatch.observer/filing/0001193125-25-056708.json
- Plain text: https://secwatch.observer/filing/0001193125-25-056708.txt

## Key facts
- Governance Changes
  Whitehawk Therapeutics, Inc.: Company amended its certificate of incorporation to change its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc (effective 2025-03-18).
  - Change: charter amendment
  - Effective: 2025-03-18
  source text: The board of directors (the “ Board ”) of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “ Charter ”), to change the Company’s name to Whitehawk Therapeutics, Inc. (the “ Name Change ”). On March 18, 2025, the Company filed a certificate of amendment (the “ Name Change Charter Amendment ”) to the Charter with the Secretary of State of the State of Delaware, which effected the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm
- Governance Changes
  Whitehawk Therapeutics, Inc.: Board approved an amendment and restatement of the bylaws solely to reflect the name change to Whitehawk Therapeutics, Inc (effective 2025-03-18).
  - Change: bylaw amendment
  - Effective: 2025-03-18
  source text: Additionally, the Board approved an amendment and restatement of the Company’s bylaws solely to reflect the Name Change (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws became effective upon the effectiveness of the Name Change Charter Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/0001193125-25-056708-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.